IL-25 Treatment Improves Metabolic Syndrome in High-Fat Diet and Genetic Models of Obesity
Allen D Smith,Anya Fan,Bolin Qin,Neemesh Desai,Aiping Zhao,Terez Shea-Donohue
DOI: https://doi.org/10.2147/DMSO.S335761
2021-12-21
Abstract:Allen D Smith, 1 Anya Fan, 2 Bolin Qin, 1 Neemesh Desai, 2 Aiping Zhao, 2 Terez Shea-Donohue 3 1 Diet, Genomics, and Immunology Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, U.S. Department of Agriculture, Beltsville, MD, USA; 2 Department of Radiation Oncology University of Maryland School of Medicine, Baltimore, MD, USA; 3 Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, USA Correspondence: Allen D Smith Diet, Genomics, and Immunology Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, U.S. Department of Agriculture, Beltsville, MD, USA Tel +1 301-504-8577 Fax +1- 301 504-9062 Email Introduction: Endemic obesity is considered the driving force for the dramatic increase in incidence of type 2 diabetes (T2D). There is mounting evidence that chronic, low-grade inflammation driven by Th1/Th17 cells and M1 macrophages, is a critical link between obesity and insulin resistance. IL-25 promotes development of a Th2 immune response and M2 macrophages that counteract the inflammation associated with obesity and T2D. Methods: Mice were fed a high-fat diet (HFD) for 16 weeks and then treated with IL-25 or BSA as a control for 21 days. Body weight, blood glucose levels, intraperitoneal glucose tolerance, and gene expression were evaluated in mice treated with BSA or IL-25. Ob/ob mice fed a normal control diet were also treated with BSA or IL-25 and body weight and blood glucose levels were measured. Transepithelial electrical resistance and sodium-linked glucose absorption were determined in muscle-free small intestinal tissue and glucose absorption assessed in vitro in intestinal epithelial and skeletal muscle cell lines. Results: Administration of IL-25 to HFD fed mice reversed glucose intolerance, an effect mediated in part by reduction in SGLT-1 activity and Glut2 expression. Importantly, the improved glucose tolerance in HFD mice treated with IL-25 was maintained for several weeks post-treatment indicating long-term changes in glucose metabolism in obese mice. Glucose intolerance was also reversed by IL-25 treatment in genetically obese ob/ob mice without inducing weight loss. In vitro studies demonstrated that glucose absorption was inhibited by IL-25 treatment in the epithelial IPEC-1 cells but increased glucose absorption in the L6 skeletal muscle cells. This supports a direct cell-specific effect of IL-25 on glucose metabolism. Conclusion: These results suggest that the IL-25 pathway may be a useful target for the treatment of metabolic syndrome. Keywords: metabolic syndrome, glucose, ob/ob, rodent Endemic obesity is considered the driving force for the dramatic increase in incidence of type 2 diabetes (T2D). Immunometabolism is an emerging field of investigation, and a major focus has been the contribution of pro-inflammatory cytokines and mediators to obesity and the disruption of metabolic homeostasis. There is mounting experimental and clinical evidence showing that chronic, low-grade inflammation is a critical link between obesity and insulin resistance. 1–3 This low-grade inflammation in obesity is found systemically, as indicated by increased circulating levels of pro-inflammatory cytokines including TNF-α, Macrophage Migration Inhibitory Factor (MIF), IL-6 4,5 and leukocytes expressing a pro-inflammatory cytokine profile in obese individuals. 5 Plasma levels of IL-12 are elevated in obese patients and recent evidence highlights IL-12 family cytokines as potential regulators linking obesity to nutrient intake and insulin resistance. 6,7 Th17 cells are associated with T2D, and IL-17A and IL-17F remain strong markers of Th17 responses. 8 In addition, low-grade inflammation is found in metabolically important tissues, such as liver and adipose tissue, and features accumulation of various types of inflammatory cells (Th1/Th17 cells, macrophages, etc.). 9 Anti-inflammatory agents are a major target for insulin-sensitizing therapies and have been validated in animal studies. 10,11 Recent clinical trials targeting pro-inflammatory cytokines/mediators (TNFα, IL-1β, Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (IKKβ)), however, were only modestly successful in treating diabetes. 12–17 IL-22, an IL-10 family member generated by type 3 innate lymphoid cells (ILC3), Th17 and Th22 cells, improved metabolic syndrome parameters in mice fed a high-fat diet (HFD) and genetically obese leptin-receptor-deficient (db/db) mice. 18 A limiting fac -Abstract Truncated-